NASDAQ:LMNX - Luminex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.05 +0.18 (+0.70 %)
(As of 02/22/2019 02:19 PM ET)
Previous Close$25.87
Today's Range$25.87 - $26.23
52-Week Range$19.20 - $35.37
Volume4,788 shs
Average Volume346,432 shs
Market Capitalization$1.16 billion
P/E Ratio54.47
Dividend Yield0.92%
Beta0.81
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$315.82 million
Cash Flow$1.0120 per share
Book Value$10.49 per share

Profitability

Net Income$18.50 million

Miscellaneous

Employees922
Market Cap$1.16 billion
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable

Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Monday, February 11th. Investors of record on Thursday, March 21st will be given a dividend of $0.06 per share on Thursday, April 11th. This represents a $0.24 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Wednesday, March 20th. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings data on Monday, February, 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.08. The medical instruments supplier earned $81.10 million during the quarter, compared to analyst estimates of $80.76 million. Luminex had a net margin of 5.81% and a return on equity of 4.61%. The company's revenue was up 3.7% compared to the same quarter last year. During the same period last year, the firm posted $0.20 earnings per share. View Luminex's Earnings History.

When is Luminex's next earnings date?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Luminex.

What guidance has Luminex issued on next quarter's earnings?

Luminex updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $337-343 million, compared to the consensus revenue estimate of $333.79 million.Luminex also updated its FY 2018 guidance to EPS.

What price target have analysts set for LMNX?

4 brokerages have issued twelve-month price targets for Luminex's stock. Their predictions range from $22.00 to $33.00. On average, they anticipate Luminex's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for Luminex.

What is the consensus analysts' recommendation for Luminex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Has Luminex been receiving favorable news coverage?

Headlines about LMNX stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Luminex earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Micron Technology (MU), Alphabet (GOOG), Weyerhaeuser (WY), Nektar Therapeutics (NKTR), Intel (INTC), Starbucks (SBUX), Pfizer (PFE), Johnson & Johnson (JNJ), Cisco Systems (CSCO) and MONDI/PAR VTG FPD 0.2 (MNDI).

Who are Luminex's key executives?

Luminex's management team includes the folowing people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

Who are Luminex's major shareholders?

Luminex's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.65%), Dimensional Fund Advisors LP (4.41%), Acadian Asset Management LLC (3.23%), Northern Trust Corp (2.12%), Bessemer Group Inc. (1.94%) and Bank of New York Mellon Corp (1.42%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., D. E. Shaw & Co. Inc., State Board of Administration of Florida Retirement System, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Hancock Whitney Corp and PNC Financial Services Group Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex.

Which institutional investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., First Trust Advisors LP, Thomson Horstmann & Bryant Inc., Martingale Asset Management L P, Geode Capital Management LLC, Barclays PLC, Dimensional Fund Advisors LP and Rhumbline Advisers. View Insider Buying and Selling for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $26.05.

How big of a company is Luminex?

Luminex has a market capitalization of $1.16 billion and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.50 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 922 workers across the globe.

What is Luminex's official website?

The official website for Luminex is http://www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (NASDAQ LMNX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel